Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperphosphatemia in multiple myeloma

S Oren1, A Feldman, S Turkot

  • 1Department of Internal Medicine A, Barzilai Medical Center, Ashkelon, Israel.

Annals of Hematology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody-positive subjects over six years of follow-up.

Journal of internal medicine·2019
Same author

Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach.

Diabetes & metabolism·2018
Same author

Deposition of Diamond Films in a Closed Hot Filament CVD System.

Journal of research of the National Institute of Standards and Technology·2017
Same author

Morbidity and mortality associated with rewarming hypothermic very low birth weight infants.

Journal of neonatal-perinatal medicine·2016
Same author

Late Relapse in Hodgkin's Disease: Report of Five Cases and a Review of the Literature.

Leukemia & lymphoma·2016
Same author

Chronic Lymphocytic Leukemia in Young Adults: Report of Six Cases Under the Age of 30 Years.

Leukemia & lymphoma·2016
Same journal

Low- to moderate-dose thalidomide combination rescue after luspatercept failure in transfusion-dependent β-thalassemia: a real-world cohort study.

Annals of hematology·2026
Same journal

Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece.

Annals of hematology·2026
Same journal

Comparative thromboembolic risk of romiplostim versus eltrombopag in immune thrombocytopenia: a propensity score-matched cohort study.

Annals of hematology·2026
Same journal

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Annals of hematology·2026
Same journal

Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study.

Annals of hematology·2026
Same journal

Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.

Annals of hematology·2026
See all related articles

Multiple myeloma patients can experience pseudohyperphosphatemia due to paraprotein interference with lab assays. This spurious finding, unrelated to kidney function, may fluctuate with disease activity.

Area of Science:

  • Clinical Chemistry
  • Hematology
  • Oncology

Background:

  • Multiple myeloma is a plasma cell malignancy.
  • Pseudohyperphosphatemia can mimic true hyperphosphatemia.
  • Paraproteins may interfere with laboratory assays.

Observation:

  • Three IgG kappa multiple myeloma patients presented with pseudohyperphosphatemia.
  • Serum calcium and renal function were normal.
  • No hypoparathyroidism or exogenous phosphate administration was noted.

Findings:

  • The pseudohyperphosphatemia was deemed spurious, with normal 1,25 dihydroxy vitamin D3 levels.
  • Interference of paraprotein with a chromogenic assay caused the elevated phosphate readings.
  • Phosphate levels fluctuated with changes in globulin and paraprotein levels during therapy and relapse.

Related Experiment Videos

Implications:

  • This highlights the importance of recognizing spurious hyperphosphatemia in multiple myeloma.
  • Assay interference by paraproteins should be considered in diagnosing electrolyte abnormalities.
  • Monitoring phosphate levels may require adjustments based on myeloma activity and paraprotein levels.